Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma

By afschroeder • July 14, 2026

Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Jul 14:1-9. doi: 10.1080/14796694.2026.2698699. Epub ahead of print. PMID: 42444515.

Tags: chart review, daratumumab, frontline, Hematology/Oncology, Multiple myeloma, Progression-free survival, Publications, real-world, transplant-eligible

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri[...]

Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape

Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026 Jul 13:JCO2600672.[...]